You are currently viewing Mind Cure Signs LOI to Acquire an Ownership Interest in Psychedelic Treatment Center ATMA, Selected by Section 56 Exempt Patient for Psilocybin Therapy

Mind Cure Signs LOI to Acquire an Ownership Interest in Psychedelic Treatment Center ATMA, Selected by Section 56 Exempt Patient for Psilocybin Therapy

The strategic partnership between Mind Cure and ATMA will bridge access to research locations for psychedelic drug research while providing patient data for iSTRYM, Mind Cure’s digital therapeutics platform.

VANCOUVER, BC, Jan. 12, 2021 /CNW/ – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (“Mind Cure” or the “Company”) is pleased to announce the signing of a non-binding letter of intent (the “LOI“) for strategic investment and commercial cooperation with ATMA Journey Centers Inc. (“ATMA“), a Calgary-based organization. ATMA is the first commercial treatment center in Canada to announce providing psychedelic-assisted therapy for a section 56 exempt patient. The LOI is intended to help Mind Cure secure an equity position within ATMA, empowering the Company with access to a global release strategy for iSTRYM, as well as international locations for translational research on novel molecules and treatment protocols.

“ATMA’s clinicians possess a proven track record of advocacy and innovation driving toward the therapeutic benefits of psychedelic medicine for patients in the treatment of mental health and wellness. Mind Cure is extremely excited to join ATMA in the renaissance  that is disrupting mental health care by partnering with one of the pioneers in the therapeutic psychedelics industry,” said Kelsey Ramsden, President & CEO, Mind Cure. “With Mind Cure’s therapeutic tool, iSTRYM, along with ATMA’s pivotal achievement as the care provider for Canada’s most recent section 56(1) exempt patient, mental health care in Canada is making history. We are thrilled to work with the best-in-class to drive our focus on accelerating our research and technology platforms.”

Mind Cure’s partnership with ATMA is an exciting opportunity for researchers and therapists to participate in each of Mind Cure’s research programs focused on pain, neuroregeneration, migraines, and cluster headaches. The proposed investment will facilitate the syndication of Mind Cure’s psychedelic drug protocols and the use of Mind Cure’s proprietary technology, iSTRYM, to optimize treatment for ATMA clients.

The deployment of capital will also advance speed and scale for data enrichment of iSTRYM, providing the AI-driven platform with access to patient data as ATMA targets domestic and international healing and treatment centers.

“Psilocybin-assisted therapy offers healing and understanding that is unmatched by traditional methods. Patients dealing with end-of-life anxiety, pain, depression, trauma, and addiction have been at the mercy of ineffective and underwhelming treatments for much too long. The resources are here, and we are extremely grateful to be at the frontlines of this world-changing, innovative, and extremely alleviating solution, to help bring peace to sufferers,” said David Harder, co-CEO, ATMA Journey Centers Inc. “We are witnessing an inflection point for mental health treatment as the commitment to wellness in Canada takes a huge step forward.”

Pursuant to the LOI, the parties intend to negotiate the terms of definitive agreements (the “Definitive Agreements“), which will provide for, among other things an initial $500,000 investment by Mind Cure in ATMA, participation by Mind Cure in ATMA’s future financings, and the exclusive use of iSTRYM throughout ATMA’s business. There can be no assurance that the Definitive Agreements will be entered into or that the investment or commercial transactions will be completed on the terms proposed in the LOI or at all.

About ATMA Journey Centers Inc. and SYNTAC Institute

ATMA is a private healthcare company with the mission of delivering effective and innovative healing and transformative experiences that awaken the inner healer and promote a deeper connection with the self, with others, and with the beauty of the world. ATMA is the first private sector service provider in Canada to announce psychedelic-assisted therapy provision under the approval of Health Canada’s Section 56(1) exemption, which will allow ATMA to provide psilocybin-assisted therapy to those seeking psychedelic assisted therapy.

ATMA’s founding members, David Harder, Greg Habstritt, and Vu Tran, also founded SYNTAC Institute, a non-profit organization with the mission of bringing the healing and transformative power of psychedelic medicine and psychedelic-assisted therapy to Canadians. SYNTAC has been an influential participant in the Canadian psychedelic medicine industry and operates Catalyst Presents, a series of conferences and summits in Canada focused on psychedelics.

About Mind Cure Health Inc.

Mind Cure exists as a response to the current mental health crisis and urgent calls for effective treatments. Mind Cure believes in the need to reinvent the mental health care model for patients and practitioners to allow psychedelics to advance into common and accepted care.

Mind Cure is focused on identifying and developing pathways and products that ease suffering, increase productivity, and enhance mental health. Mind Cure is interested in exploring diverse therapeutic areas beyond psychiatry, including digital therapeutics, neuro-supports, and psychedelics, all to improve mental health.

On Behalf of the Board of Directors
Kelsey Ramsden, President & CEO
Phone: 1-888-593-8995

Forward-Looking Information

Certain statements in this news release may constitute “forward-looking information” within the meaning of applicable securities laws (also known as forward-looking statements). Forward-looking information involves known and unknown risks, uncertainties and other factors, and may cause actual results, performance or achievements or industry results, to be materially different from any future results, performance or achievements or industry results expressed or implied by such forward-looking information. Forward-looking information generally can be identified by the use of terms and phrases such as “anticipate”, “believe”, “could”, “estimate”, “expect”, “feel”, “intend”, “may”, “plan”, “predict”, “project”, “subject to”, “will”, “would”, and similar terms and phrases, including references to assumptions. Some of the specific forward-looking information in this news release includes, but is not limited to, statements with respect to: the conclusion of the transactions and negotiation of the Definitive Agreements contemplated by the LOI on the terms disclosed herein, or at all; ATMA conducting additional psychedelic-assisted therapy; the disruption of mental health care through psychedelic-based therapies; the development of iSTRYM and incorporation into ATMA’s business; the relationship with ATMA accelerating the development of Mind Cure’s research and technology platforms; participation of researchers and therapists in Mind Cure’s research programs; Mind Cure’s investment facilitating the syndication of Mind Cure’s psychedelic drug protocols and the development of those protocols; protocols and iSTRYM to optimize treatment for ATMA clients and driving greater access to patient data for the AI-driven digital therapeutics platform; the roll-out of domestic and international treatment centres by ATMA; the realization of an inflexion point for mental health treatment; and Mind Cure’s collection of data from ATMA’s section 56 exempt clients.

Forward-looking information is based on a number of key expectations and assumptions made by Mind Cure, including, without limitation: the COVID-19 pandemic impact on the Canadian economy and Mind Cure’s business, and the extent and duration of such impact; no change to laws or regulations that negatively affect Mind Cure’s business; there will be a demand for Mind Cure’s products and ATMA’s clinics in the future; no unanticipated expenses or costs arise; Mind Cure will be able to continue to identify products that make them ideal candidates for providing solutions for treating mental health; the partnership with ATMA will help Mind Cure achieve its business goals; and Mind Cure will be able to operate its business as planned. Although the forward-looking information contained in this news release is based upon what Mind Cure believes to be reasonable assumptions, it cannot assure investors that actual results will be consistent with such information.

Forward-looking information is provided for the purpose of presenting information about management’s current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. Forward-looking information involves significant risks and uncertainties and should not be read as a guarantee of future performance or results as actual results may differ materially from those expressed or implied in such forward-looking information. Those risks and uncertainties include, among other things, risks related to: the impacts of the COVID-19 pandemic on the Canadian economy, Mind Cure’s industry and Mind Cure’s business, which may negatively impact, and may continue to negatively impact, Mind Cure and may materially adversely affect Mind Cure’s investments, results of operations, financial condition, and Mind Cure’s ability to obtain additional equity or debt financing, and satisfy its financial obligations; general economic conditions; future growth potential; competition for mental health and wellness investments; Mind Cure’s partnership with ATMA may not help Mind Cure achieve its business goals; iSTRYM, and its database function may not be successfully developed or help to optimize protocols and enhance scientific research; and changes in legislation or regulations. Management believes that the expectations reflected in the forward-looking information contained herein are based upon reasonable assumptions and information currently available; however, management can give no assurance that actual results will be consistent with such forward-looking information. Additional information on the risk factors that could affect Mind Cure can be found under “Risk Factors” in Mind Cure’s final prospectus which is available on SEDAR at

The forward-looking information contained herein is expressly qualified in its entirety by this cautionary statement. Forward-looking information reflects management’s current beliefs and is based on information currently available to Mind Cure. The forward-looking information is stated as of the date of this news release and Mind Cure assumes no obligation to update or revise such information to reflect new events or circumstances, except as may be required by applicable law.

The CSE has neither approved nor disapproved the contents of this press release and the CSE does not accept responsibility for the adequacy or accuracy of this release.

SOURCE Mind Cure Health Inc.

For further information: Investor Relations: 1-888-593-8995